证券日报网讯2月27日，一心堂（002727）在互动平台回答投资者提问时表示，公司主营业务为药品零 售连锁，并发展中药产业与医养业务，构建康养生态圈，满足市场需求，为顾客提供更优质便捷的服 务。目前经营模式还在不断优化中，经营质量也在持续改善。 ...

Core Viewpoint - Dazhonglin has been recognized as a leading company in ESG practices within the pharmaceutical retail industry, marking a significant achievement in its sustainable development strategy [1][2] Group 1: Company Overview - Dazhonglin, one of China's largest chain pharmacies, had 17,385 stores as of the end of Q3 2025, including 7,029 franchise stores, with a total operating area of 887,503 square meters [1] - In the first nine months of 2025, the company added 832 new stores, continuing its strategy of expanding its presence in South China while penetrating weaker regions through self-built, acquisition, and direct franchise models [1] Group 2: ESG Practices - Dazhonglin has achieved quantifiable results in its ESG initiatives, including energy management, the use of new energy delivery vehicles, and the implementation of paperless operations, resulting in approximately 154.33 million kWh of solar power generated in 2024 and saving around 25.24 million cardboard boxes [2] - The company has engaged in community service through public donations and health management services, conducting over 40,000 health education activities and providing health monitoring services to over 1 million residents, positioning itself as a "community health service station" [2] - Dazhonglin emphasizes strong corporate governance as a foundation for sustainable development, maintaining a transparent governance structure and robust risk management, which supports its compliance and ethical business practices [2] Group 3: Future Outlook - The company's ESG practices reflect a shift from compliance management to value-driven operations, enhancing its long-term competitiveness and providing a reference for sustainable development in the industry [2] - With the growing demand for chronic disease management in an aging society, Dazhonglin's integrated approach of "medicine + pharmacy + insurance" is expected to further unlock synergies between ESG and commercial value [2]

Group 1: Gushengtang (2273.HK) Overview - Gushengtang is accelerating its overseas expansion and increasing share buybacks, with projected revenues of 34.31, 43.14, and 51.80 billion CNY for 2025-2027, representing year-on-year growth of 13.52%, 25.75%, and 20.07% respectively [3][5] - The company plans to acquire 100% of Dazhongtang PTE. LTD., enhancing its presence in Singapore's traditional Chinese medicine market and adding 14 new clinics [3][4] - The share buyback program, totaling up to 600 million HKD, reflects the company's confidence in its long-term business prospects and aims to enhance shareholder value [4][5] Group 2: Aladdin (688179.SH) Overview - Aladdin is expanding its product matrix through the acquisition of 35% of Youke Instrument for 61.25 million CNY, which specializes in laboratory analysis instruments [6][8] - The acquisition is expected to enhance Aladdin's product offerings and customer engagement, leveraging its existing resources and channels [6][7] - Aladdin has completed six investment projects since 2023, diversifying its product lines in various fields, including recombinant proteins and biochemical reagents [7]

Investment Rating - The report assigns an "Outperform" rating to Gushengtang, expecting a relative return exceeding 10% over the next 12-18 months [16]. Core Insights - Gushengtang announced the acquisition of 100% equity in Singapore's Da Zhong Tang, which operates 14 TCM clinics, aiming to enhance its market share and expand its business network in Singapore [5][6]. - The acquisition is anticipated to positively impact the company's performance in 2026, leveraging Da Zhong Tang's established brand and operational presence in key commercial areas of Singapore [6][7]. - The company plans to continue its overseas expansion through a combination of mergers and acquisitions, partnerships, and self-established clinics, targeting the addition of 10-20 new stores in Singapore and around 20 clinics in Hong Kong by 2026 [7][8]. Summary by Sections Acquisition Details - Gushengtang's acquisition of Da Zhong Tang will consolidate its financial results into the group's statements, enhancing its operational scale in Singapore [5][6]. Market Expansion Strategy - The company aims to expand its presence in Singapore through a mix of M&A, partnerships, and new clinic establishments, with a goal of generating significant overseas revenue by 2026 [7]. Operational Enhancements - Gushengtang plans to utilize its domestic supply chain for Chinese herbal products to support its overseas clinics, while enhancing internal treatment capabilities through AI technology and expert training [8].

Core Viewpoint - Gushengtang Singapore is acquiring 100% equity and related interests of DA ZHONG TANG PTE. LTD., which will become a subsidiary of the company, enhancing its presence in the Singapore market and expanding its offline medical network [1] Group 1 - The acquisition agreement was signed on November 16, 2025, between Gushengtang Singapore and the shareholders of DA ZHONG TANG [1] - Following the completion of the acquisition, DA ZHONG TANG will be included in the group's consolidated financial statements [1] - DA ZHONG TANG primarily provides traditional Chinese medicine services and retail pharmaceutical services in Singapore [1] Group 2 - The acquisition aligns with the company's strategy to expand its offline medical institution network through acquisitions [1] - The company anticipates that the acquisition will increase its market share in Singapore and create synergies between DA ZHONG TANG and the group's other offline medical institutions and online medical platforms [1]

Core Viewpoint - YaoXingTang (002727) focuses on retail pharmacy chains, supplemented by traditional Chinese medicine to meet diverse consumer medication needs [1] Company Summary - The company operates primarily in the retail pharmacy chain business [1] - It incorporates traditional Chinese medicine as a complementary service to enhance its retail offerings [1] - The strategy aims to satisfy the varied medication service demands of consumers [1]

Core Viewpoint - Dazhonglin has implemented a high dividend payout strategy, distributing a total of 7.02 billion yuan in cash dividends for the year, reflecting a strong commitment to shareholder returns and confidence in its operational strength amid market complexities [1][2]. Financial Performance - In 2024, Dazhonglin achieved a revenue of 26.497 billion yuan and a net profit attributable to shareholders of 915 million yuan [1]. - For the first quarter of 2025, the company reported a revenue of 6.956 billion yuan, representing a year-on-year growth of 3.02%, and a net profit of 460 million yuan, showing a year-on-year increase of 15.45% [1][2]. Dividend Policy - The company distributed a cash dividend of 3.1 yuan per 10 shares (including tax) to all shareholders, totaling 351 million yuan [1]. - Dazhonglin has maintained a high dividend payout ratio of 76.73%, with a dividend yield of 3.98%, ranking among the top in its sector [1][2]. - Since its listing in 2017, Dazhonglin has cumulatively distributed cash dividends amounting to 3.355 billion yuan, with a dividend payment ratio of 76.73% and a financing payout ratio of 98.84% [1]. Store Expansion and Market Position - As of March 2025, Dazhonglin operated a total of 16,622 stores, including 6,239 franchise stores and 10,383 direct stores, marking a net increase of 2,588 stores since the beginning of 2024 [2]. - The company aims to enhance its market share in already covered regions, leveraging its scale advantages to further solidify its position as a leading chain pharmacy in China [2]. Future Outlook - Dazhonglin is expected to strengthen its leadership in the pharmaceutical retail sector, driven by ongoing industry transformations and increasing consumer demand for quality and personalized health products [2].